Literature DB >> 2995557

Inhibition of herpes simplex virus replication in vitro by human cytotoxic T cell clones and natural killer cell clones.

M Yasukawa, Y Kobayashi.   

Abstract

The abilities of human cytotoxic T cell (CTL) clones and natural killer (NK) cell clones to inhibit the replication of herpes simplex virus (HSV) in vitro were shown. The specificities of clones inhibiting HSV replication were the same as those of cytotoxicity in HSV type specificity and HLA restriction, i.e. HSV type 1 (HSV-1) and HSV type 2 (HSV-2) common CTL clones inhibited the replication of both HSV-1 and HSV-2 in autologous cells, but not in allogeneic cells. HSV-1-specific CTL clones inhibited the replication of HSV-1 in autologous cells; however, the replication of HSV-2 was not inhibited. NK cell clones inhibited the replication of HSV-1 and HSV-2 in autologous and allogeneic cells. This is the first demonstration that human virus-specific CTL clones and NK cell clones directly limit virus replication in vitro.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2995557     DOI: 10.1099/0022-1317-66-10-2225

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  11 in total

1.  Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes.

Authors:  D M Koelle; C M Posavad; G R Barnum; M L Johnson; J M Frank; L Corey
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

2.  Rotavirus induces proliferative response and augments non-specific cytotoxic activity of lymphocytes in humans.

Authors:  M Yasukawa; O Nakagomi; Y Kobayashi
Journal:  Clin Exp Immunol       Date:  1990-04       Impact factor: 4.330

3.  CD4 T-cell responses to herpes simplex virus type 2 major capsid protein VP5: comparison with responses to tegument and envelope glycoproteins.

Authors:  D M Koelle; M Schomogyi; C McClurkan; S N Reymond; H B Chen
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D.

Authors:  Xiuli Zhang; Florence A Castelli; Xiaoming Zhu; Michele Wu; Bernard Maillère; Lbachir BenMohamed
Journal:  Clin Vaccine Immunol       Date:  2008-07-30

5.  Anti-glycoprotein D monoclonal antibody protects against herpes simplex virus type 1-induced diseases in mice functionally depleted of selected T-cell subsets or asialo GM1+ cells.

Authors:  H F Staats; J E Oakes; R N Lausch
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

6.  Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B.

Authors:  Aziz Alami Chentoufi; Nicholas R Binder; Noureddine Berka; Guillaume Durand; Alex Nguyen; Ilham Bettahi; Bernard Maillère; Lbachir BenMohamed
Journal:  J Virol       Date:  2008-09-17       Impact factor: 5.103

7.  Antigenic specificities of human CD4+ T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions.

Authors:  D M Koelle; L Corey; R L Burke; R J Eisenberg; G H Cohen; R Pichyangkura; S J Triezenberg
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

Review 8.  Recent progress in herpes simplex virus immunobiology and vaccine research.

Authors:  David M Koelle; Lawrence Corey
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

9.  HSV-2-Specific Human Female Reproductive Tract Tissue Resident Memory T Cells Recognize Diverse HSV Antigens.

Authors:  David M Koelle; Lichun Dong; Lichen Jing; Kerry J Laing; Jia Zhu; Lei Jin; Stacy Selke; Anna Wald; Dana Varon; Meei-Li Huang; Christine Johnston; Lawrence Corey; Christine M Posavad
Journal:  Front Immunol       Date:  2022-03-31       Impact factor: 8.786

10.  Inhibition of transmissible gastroenteritis coronavirus (TGEV) multiplication in vitro by non-immune lymphocytes.

Authors:  B Charley; H Laude; C La Bonnardière
Journal:  Ann Inst Pasteur Virol       Date:  2009-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.